All In Biotech

Drug Trial Radar · NCT06619951

A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Dec 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Sep 18, 2024

Primary completion

Oct 31, 2024

Study completion Oct 31, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will adopt a Single-center, Single-arm, Open, Fixed Sequence design to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects.

Conditions

  • Locally Advanced or Metastatic Solid Tumor

Interventions

  • VC004 and ItraconazoleDrug

    A single dose of VC004 was administered in the period 1. and a single dose of VC004 and Itraconazole coadministration in the period 2.

  • VC004 and rifampicinDrug

    A single dose of VC004 was administered in the period 1. and a single dose of VC004 and rifampicin coadministration in the period 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Day1-Day16
  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC)Time frame: Day1-Day16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongda Hospital,Affiliated to Southeast University

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.